Your browser doesn't support javascript.
Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children.
Li, Nina; Li, XueYun; Wu, Jiani; Zhang, Shengze; Zhu, Lin; Chen, Qiqi; Fan, Ying; Wu, Zhengyu; Xie, Sidian; Chen, Qi; Wang, Ning; Wu, Nan; Luo, Chuming; Shu, Yuelong; Luo, Huanle.
  • Li N; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • Li X; School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
  • Wu J; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • Zhang S; School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
  • Zhu L; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • Chen Q; School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
  • Fan Y; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • Wu Z; School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
  • Xie S; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • Chen Q; School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
  • Wang N; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • Wu N; School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
  • Luo C; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • Shu Y; School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
  • Luo H; School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
Front Immunol ; 13: 1042406, 2022.
Article in English | MEDLINE | ID: covidwho-2099154
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes asymptomatic or mild symptoms, even rare hospitalization in children. A major concern is whether the pre-existing antibodies induced by low pathogenic human coronaviruses (LPH-CoVs) in children can cross-react with SARS-CoV-2. To address this unresolved question, we analyzed the pre-existing spike (S)-specific immunoglobin (Ig) G antibodies against LPH-CoVs and the cross-reactive antibodies against SARS-CoV-2 in 658 serum samples collected from children prior to SARS-CoV-2 outbreak. We found that the seroprevalence of these four LPH-CoVs reached 75.84%, and about 24.64% of the seropositive samples had cross-reactive IgG antibodies against the nucleocapsid, S, and receptor binding domain antigens of SARS-CoV-2. Additionally, the re-infections with different LPH-CoVs occurred frequently in children and tended to increase the cross-reactive antibodies against SARS-CoV-2. From the forty-nine serum samples with cross-reactive anti-S IgG antibodies against SARS-CoV-2, we found that seven samples with a median age of 1.4 years old had detected neutralizing activity for the wild-type or mutant SARS-CoV-2 S pseudotypes. Interestingly, all of the seven samples contained anti-S IgG antibodies against HCoV-OC43. Together, these data suggest that children's pre-existing antibodies to LPH-CoVs have limited cross-reactive neutralizing antibodies against SRAS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronaviridae / COVID-19 Type of study: Observational study / Randomized controlled trials Limits: Child / Humans / Infant Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1042406

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronaviridae / COVID-19 Type of study: Observational study / Randomized controlled trials Limits: Child / Humans / Infant Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1042406